Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 14/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123965 | 1.00 | PTK6 (0.55) | PTK6HTR4LCKAURKBMAPKAPK5 | |
| SCHEMBL22122944 | 0.93 | PTK6 (0.47) | PTK6HTR4LCKAURKBMAPKAPK5 | |
| SCHEMBL22122928 | 0.90 | PTK6 (0.51) | PTK6HTR4LCKAURKBEGFR | |
| SCHEMBL30171940 | 0.90 | PTK6 (0.51) | PTK6HTR4LCKAURKBEGFR | |
| SCHEMBL30183184 | 0.89 | TTK (0.46) | PTK6AURKBMAPKAPK5EGFRCD274 | |
| SCHEMBL22139120 | 0.88 | PTK6 (0.54) | PTK6LCKAURKBMAPKAPK5EGFR | |
| Hydrochloric Acid SCHEMBL30171709 | 0.87 | PTK6 (0.53) | PTK6LCKAURKBMAPKAPK5EGFR | |
| SCHEMBL22123797 | 0.87 | PTK6 (0.45) | PTK6AURKBMAPKAPK5EGFRCD274 | |
| SCHEMBL22124775 | 0.87 | PTK6 (0.45) | PTK6LCKAURKBMAPKAPK5EGFR | |
| SCHEMBL22123074 | 0.86 | TTK (0.45) | PTK6AURKBMAPKAPK5CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885HTR4 3666/4885LCK 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.